Skip to main content
Erschienen in: Der Urologe 3/2019

28.02.2019 | Prostatakarzinom | CME

Active Surveillance beim Prostatakarzinom

Ein Update

verfasst von: Dr. med. M. Chaloupka, T. Westhofen, A. Kretschmer, T. Grimm, C. Stief, M. Apfelbeck

Erschienen in: Die Urologie | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Prostatakarzinom ist eine heterogene Erkrankung. Im Falle eines Niedrigrisikokarzinoms stellt die aktive Überwachung eine attraktive Therapiealternative dar. Einschneidende Komplikationen einer definitiven Therapie können somit aufgeschoben bzw. ganz vermieden werden. Trotz strenger Einschlusskriterien für die aktive Überwachung ist die Diagnose eines Niedrigrisikokarzinoms aber nicht immer korrekt gestellt. Es verbleibt ein Risiko, dass der optimale Zeitpunkt einer definitiven Therapie verpasst wird. Eine multimodale Diagnostik sowie eine engmaschige Nachsorge sind deswegen essenziell.
Literatur
1.
Zurück zum Zitat Zentrum für Krebsregisterdaten (2017) Robert-Koch-Institut: Krebs in Deutschland, Prostata Zentrum für Krebsregisterdaten (2017) Robert-Koch-Institut: Krebs in Deutschland, Prostata
3.
Zurück zum Zitat Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M (2016) Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 69:576–581CrossRef Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M (2016) Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 69:576–581CrossRef
4.
Zurück zum Zitat Auffenberg GB, Linsell S, Dhir A, Myers SN, Rosenberg B, Miller DC, Michigan Urological Surgery Improvement C (2016) Comparison of pathological outcomes for men with low risk prostate cancer from diverse practice settings: similar results from immediate prostatectomy or initial surveillance with delayed prostatectomy. J Urol 196:1415–1421CrossRef Auffenberg GB, Linsell S, Dhir A, Myers SN, Rosenberg B, Miller DC, Michigan Urological Surgery Improvement C (2016) Comparison of pathological outcomes for men with low risk prostate cancer from diverse practice settings: similar results from immediate prostatectomy or initial surveillance with delayed prostatectomy. J Urol 196:1415–1421CrossRef
5.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRef D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRef
6.
Zurück zum Zitat Carter HB, Walsh PC, Landis P, Epstein JI (2002) Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167:1231–1234CrossRef Carter HB, Walsh PC, Landis P, Epstein JI (2002) Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167:1231–1234CrossRef
7.
Zurück zum Zitat Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 314:80–82CrossRef Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 314:80–82CrossRef
8.
Zurück zum Zitat Loppenberg B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, Barry H, Lipsitz SR, Menon M, Abdollah F et al (2018) Variation in the use of active surveillance for low-risk prostate cancer. Cancer 124:55–64CrossRef Loppenberg B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, Barry H, Lipsitz SR, Menon M, Abdollah F et al (2018) Variation in the use of active surveillance for low-risk prostate cancer. Cancer 124:55–64CrossRef
9.
Zurück zum Zitat Huland H, Graefen M (2015) Changing trends in surgical management of prostate cancer: the end of overtreatment? Eur Urol 68:175–178CrossRef Huland H, Graefen M (2015) Changing trends in surgical management of prostate cancer: the end of overtreatment? Eur Urol 68:175–178CrossRef
11.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629CrossRef Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629CrossRef
12.
Zurück zum Zitat Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRef Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374CrossRef
13.
Zurück zum Zitat Kryvenko ON, Carter HB, Trock BJ, Epstein JI (2014) Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 83:869–874CrossRef Kryvenko ON, Carter HB, Trock BJ, Epstein JI (2014) Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 83:869–874CrossRef
14.
Zurück zum Zitat Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ, group Ps (2016) A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954–960CrossRef Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ, group Ps (2016) A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954–960CrossRef
15.
Zurück zum Zitat Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190CrossRef Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190CrossRef
16.
Zurück zum Zitat Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schroder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677CrossRef Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schroder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677CrossRef
17.
Zurück zum Zitat Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRef Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131CrossRef
18.
Zurück zum Zitat Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR (2011) Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 29:2795–2800CrossRef Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR (2011) Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 29:2795–2800CrossRef
19.
Zurück zum Zitat Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE et al (2015) Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol 194:343–349CrossRef Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE et al (2015) Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol 194:343–349CrossRef
20.
Zurück zum Zitat Song SH, Pak S, Park S, Song C, Jeong IG, Choi HJ, Kim JK, Cho KS, Kim CS, Ahn H (2014) Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D’Amico criteria: role of multiparametric magnetic resonance imaging. J Urol 192:402–408CrossRef Song SH, Pak S, Park S, Song C, Jeong IG, Choi HJ, Kim JK, Cho KS, Kim CS, Ahn H (2014) Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D’Amico criteria: role of multiparametric magnetic resonance imaging. J Urol 192:402–408CrossRef
21.
Zurück zum Zitat Weiner AB, Patel SG, Eggener SE (2015) Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol 33:164 e11–164 e17CrossRef Weiner AB, Patel SG, Eggener SE (2015) Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol 33:164 e11–164 e17CrossRef
22.
Zurück zum Zitat Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB (2012) Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 187:1620–1625CrossRef Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB (2012) Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol 187:1620–1625CrossRef
23.
Zurück zum Zitat Imnadze M, Sjoberg DD, Vickers AJ (2016) Adverse pathologic features at radical prostatectomy: effect of preoperative risk on oncologic outcomes. Eur Urol 69:143–148CrossRef Imnadze M, Sjoberg DD, Vickers AJ (2016) Adverse pathologic features at radical prostatectomy: effect of preoperative risk on oncologic outcomes. Eur Urol 69:143–148CrossRef
24.
Zurück zum Zitat Beauval JB, Ploussard G, Soulie M, Pfister C, Van Agt S, Vincendeau S, Larue S, Rigaud J, Gaschignard N, Roupret M et al (2012) Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 80:656–660CrossRef Beauval JB, Ploussard G, Soulie M, Pfister C, Van Agt S, Vincendeau S, Larue S, Rigaud J, Gaschignard N, Roupret M et al (2012) Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 80:656–660CrossRef
25.
Zurück zum Zitat Carlsson S, Jaderling F, Wallerstedt A, Nyberg T, Stranne J, Thorsteinsdottir T, Carlsson SV, Bjartell A, Hugosson J, Haglind E et al (2016) Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial. BJU Int 118:205–212CrossRef Carlsson S, Jaderling F, Wallerstedt A, Nyberg T, Stranne J, Thorsteinsdottir T, Carlsson SV, Bjartell A, Hugosson J, Haglind E et al (2016) Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial. BJU Int 118:205–212CrossRef
26.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2018) Interdiszplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2018) Interdiszplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms
27.
Zurück zum Zitat Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2015) Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic Meta-analysis. Eur Urol 67:1112–1121CrossRef Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2015) Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic Meta-analysis. Eur Urol 67:1112–1121CrossRef
29.
Zurück zum Zitat Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA et al (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRef Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F, Padhani AR, Margolis D, Macura KJ, Haider MA et al (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRef
30.
Zurück zum Zitat van der Leest M, Cornel E, Israel B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J et al (2018) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective Multicenter clinical study. Eur Urol. https://doi.org/10.1016/j.eururo.2018.11.023 CrossRefPubMed van der Leest M, Cornel E, Israel B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J et al (2018) Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective Multicenter clinical study. Eur Urol. https://​doi.​org/​10.​1016/​j.​eururo.​2018.​11.​023 CrossRefPubMed
31.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777CrossRef Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777CrossRef
32.
Zurück zum Zitat Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL et al (2011) A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655CrossRef Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL et al (2011) A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655CrossRef
33.
Zurück zum Zitat Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921–927CrossRef Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921–927CrossRef
34.
Zurück zum Zitat Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A et al (2013) Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 63:986–994CrossRef Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A et al (2013) Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 63:986–994CrossRef
35.
Zurück zum Zitat Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A (2013) Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59:306–314CrossRef Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A (2013) Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59:306–314CrossRef
36.
Zurück zum Zitat Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ et al (2016) Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 70:740–748CrossRef Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ et al (2016) Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol 70:740–748CrossRef
37.
Zurück zum Zitat Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC et al (2014) A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66:550–560CrossRef Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC et al (2014) A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66:550–560CrossRef
38.
Zurück zum Zitat Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T et al (2015) A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol 68:123–131CrossRef Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T et al (2015) A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol 68:123–131CrossRef
39.
Zurück zum Zitat Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW (2009) Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 15:7316–7321CrossRef Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW (2009) Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 15:7316–7321CrossRef
40.
Zurück zum Zitat Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y (2014) The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140:257–263CrossRef Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y (2014) The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140:257–263CrossRef
41.
Zurück zum Zitat Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB et al (2012) Association of [−2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 188:1131–1136CrossRef Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB et al (2012) Association of [−2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 188:1131–1136CrossRef
43.
Zurück zum Zitat de Camargo Cancela M, Comber H, Sharp L (2013) Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer 109:272–279CrossRef de Camargo Cancela M, Comber H, Sharp L (2013) Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer 109:272–279CrossRef
44.
Zurück zum Zitat Lee JK, Sjoberg DD, Miller MI, Vickers AJ, Mulhall JP, Ehdaie B (2018) Improved recovery of erectile function in younger men after radical prostatectomy: does it justify immediate surgery in low-risk patients? Eur Urol 73:33–37CrossRef Lee JK, Sjoberg DD, Miller MI, Vickers AJ, Mulhall JP, Ehdaie B (2018) Improved recovery of erectile function in younger men after radical prostatectomy: does it justify immediate surgery in low-risk patients? Eur Urol 73:33–37CrossRef
45.
Zurück zum Zitat Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS (2017) Targeted biopsy to detect gleason score upgrading during active surveillance for men with low versus intermediate risk prostate cancer. J Urol 197:632–639CrossRef Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS (2017) Targeted biopsy to detect gleason score upgrading during active surveillance for men with low versus intermediate risk prostate cancer. J Urol 197:632–639CrossRef
46.
Zurück zum Zitat Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ (2017) The contemporary role of multiparametric magnetic resonance imaging in active surveillance for prostate cancer. Curr Urol Rep 18:52CrossRef Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ (2017) The contemporary role of multiparametric magnetic resonance imaging in active surveillance for prostate cancer. Curr Urol Rep 18:52CrossRef
47.
Zurück zum Zitat Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277CrossRef Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277CrossRef
48.
Zurück zum Zitat O’Callaghan C, Dryden T, Hyatt A, Brooker J, Burney S, Wootten AC, White A, Frydenberg M, Murphy D, Williams S et al (2014) ‘What is this active surveillance thing?’ Men’s and partners’ reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. Psychooncology 23:1391–1398CrossRef O’Callaghan C, Dryden T, Hyatt A, Brooker J, Burney S, Wootten AC, White A, Frydenberg M, Murphy D, Williams S et al (2014) ‘What is this active surveillance thing?’ Men’s and partners’ reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. Psychooncology 23:1391–1398CrossRef
49.
Zurück zum Zitat Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424CrossRef Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424CrossRef
50.
Zurück zum Zitat Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33:3379–3385CrossRef Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33:3379–3385CrossRef
51.
Zurück zum Zitat Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M, Van Poppel H (2018) Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 74:357–368CrossRef Briganti A, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M, Van Poppel H (2018) Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 74:357–368CrossRef
Metadaten
Titel
Active Surveillance beim Prostatakarzinom
Ein Update
verfasst von
Dr. med. M. Chaloupka
T. Westhofen
A. Kretschmer
T. Grimm
C. Stief
M. Apfelbeck
Publikationsdatum
28.02.2019
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 3/2019
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-019-0894-5

Weitere Artikel der Ausgabe 3/2019

Der Urologe 3/2019 Zur Ausgabe